Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV announced submission of MAA to EMA for a single-tablet, two-drug regimen of DTG and 3TC for the treatment of HIV-1 infection.
GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
GSK will profile the growing evidence base that supports its broad respiratory medicines portfolio at ERS congress in Paris, France, 09/18.
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
Nucala demonstrated greater reduction in exacerbations and improved asthma control.
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc(LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
ATLAS study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen
Iain Mackay appointed GSK Chief Financial Officer
GSK today announced that Iain Mackay has been appointed GSK’s next CFO.
CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe
GSK announced, EMA's CHMP is recommending Nucala as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients.
GSK reports on outcome of the FDA Advisory Committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy
Advisory Committee provide non-binding recommendation for consideration by the FDA
GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
Multi-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes
GSK delivers improvements in sales, margins and cash flow in Q2 2018
Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.
ViiV Healthcare presents phase III data at AIDS 2018 from landmark GEMINI studies showing two-drug regimen of dolutegravir and lamivudine has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no emergence of resistance
GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads.
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018
ViiV, specialist HIV company will be presenting over 20 abstracts, including GEMINI 1 & 2 trials, at the AIDS 2018 in Amsterdam.
US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
There is substantial evidence of the effectiveness and adequate evidence of the safety of single-dose tafenoquine
James Ford appointed GSK General Counsel
James Ford, currently SVP and General Counsel for Global Pharma, will succeed Dan Troy as General Counsel, GSK.
Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
GSK today announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof.
Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules
Healthcare professionals now have more options to help protect infants from invasive meningococcal disease (IMD) caused by serogroup B